Last updated on May 2020

Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole Based on Prior Endocrine Therapy in Patients With PIK3CA Mutation With Advanced Breast Cancer Who Have Progressed on or After Prior Treatments

Brief description of study

Study assessing the efficacy and safety of alpelisib plus fulvestrant or letrozole, based on prior endocrine therapy, in patients with PIK3CA mutation with advanced breast cancer who have progressed on or after prior treatments

Clinical Study Identifier: NCT03056755

Find a site near you

Start Over

Novartis Investigative Site

Suita city, Japan
  Connect »

Novartis Investigative Site

Osaka-city, Japan
  Connect »